Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention

Journal of the National Cancer Institute

Volumn 98, Issue 5, 2006, Pages 303-315

  Castellsagué, Xavier ^a   Diaz, Mireia ^a   de Sanjosé, Silvia ^a   Muñoz, Nubia ^a   Herrero, Rolando ^b   Franceschi, Silvia ^c   Peeling, Rosanna W ^d   Ashley, Rhoda ^e   Smith, Jennifer S ^f   Snijders, Peter J F ^g   Meijer, Chris J L M ^g   Bosch, F Xavier ^a   Plummer, M ^c   Moreno, V ^a   Alonso de Ruiz, P ^h   Chichareon, S ⁱ   Ngelangel, C ^j   Eluf Neto, J ^k   Rolo A ^l   Caceres, E ^m   Santos, C ^m   Chaouki, N ⁿ   El Gueddari, B ⁿ   Hammouda, D ^o   Rajkumar, T ^p   more..

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d HEALTH CANADA   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h HOSPITAL GENERAL DE MÉXICO   (Mexico)

ⁱ PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^j UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l Lab de Anat Patologica y Citologia   (Paraguay)

^m Maes Heller Cancer Research Institute   (Peru)

ⁿ NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^o INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Algeria)

^p CANCER INSTITUTE WIA   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BLOOD SAMPLING; CANCER INCIDENCE; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CONDYLOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA HYBRIDIZATION; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HERPES SIMPLEX VIRUS 2; HORMONAL CONTRACEPTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARITY; PERSONAL HYGIENE; PRIORITY JOURNAL; SEROPREVALENCE; SEXUAL BEHAVIOR; SMOKING; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VACCINATION; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 33644764973     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj067     Document Type: Article

References (65)

1. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000;86:429-35.
2. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
3. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-9.
4. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
5. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: A study of 49 cases. Cancer 2001;93:8-15.
6. Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: No strong evidence of benefit. Br J Cancer 1995;71:894-7.
7. Raab SS. Can glandular lesions be diagnosed in pap smear cytology? Diagn Cytopathol 2000;23:127-33.
8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
9. Lacey JV Jr, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 1999;8:1079-85.
10. Altekruse SF, Lacey JV Jr, Brinton LA, Gravitt PE, Silverberg SG, Barnes WA Jr, et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol 2003;188: 657-63.
11. Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 2001;84:1219-26.
12. Lacey JV Jr, Frisch M, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001;12:153-61.
13. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study. Lancet 2002;359:1093-101.
14. Berrington DG, Sweetland S, Green J. Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: A meta-analysis. Br J Cancer 2004;90:1787-91.
15. Lacey JV Jr, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003;98:814-21.
16. Lacey JV Jr, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149-54.
17. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89:191-9.
18. Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-8.
19. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002;94:1604-13.
20. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004;111:431-9.
21. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: Pooled analysis of the IARC multicentric case - control study. Cancer Causes Control 2003;14:805-14.
22. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, et al. Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. Int J Cancer 2005;113:483-9.
23. Chaouki N, Bosch FX, Munoz N, Meijer CJ, El Gueddari B, El Ghazi A, et al. The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer 1998;75:546-54.
24. Eluf-Neto J, Booth M, Munoz N, Bosch FX, Meijer CJ, Walboomers JM. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-9.
25. Rolon PA, Smith JS, Munoz N, Klug SJ, Herrero R, Bosch X, et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000;85:486-91.
26. Santos C, Munoz N, Klug S, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966-71.
27. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders PJ, et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. Int J Cancer 2003;107:127-33.
28. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: A case-control study. J Natl Cancer Inst 1998;90:50-7.
29. Ngelangel C, Munoz N, Bosch FX, Limson GM, Festin MR, Deacon J, et al. Causes of cervical cancer in the Philippines: A case-control study. J Natl Cancer Inst 1998;90:43-9.
30. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
31. Roda Husman AM, Snijders PJ, Stel HV, Van den Brule AJ, Meijer CJ, Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995;72:412-7.
32. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
33. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26:662-7.
34. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX, et al. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001;28:187-94.
35. Smith JS, Munoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002;185:324-31.
36. Wang SP, Grayston JT. Micro immunofluorescence antibody responses in Chlamydia trachomatis infection. A review. In: Mardh PA, Holmes KK, Oriel JD, Piot P, Schachter J, editors. Chlamydial infections. Amsterdam (The Netherlands): Elsevier - Biomedical Press; 1982. p. 301-6.
37. Anciaux D, Lawrence WD, Gregoire L. Glandular lesions of the uterine cervix: Prognostic implications of human papillomavirus status. Int J Gynecol Pathol 1997;16:103-10.
38. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001;37:246-50.
39. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
40. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88:63-73.
41. Lee MF, Chang MC, Wu CH. Detection of human papillomavirus types in cervical adenocarcinoma by the polymerase chain reaction. Int J Gynaecol Obstet 1998;63:265-70.
42. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;157:1055-62.
43. Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
44. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
45. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet 2002;359:1085-92.
46. Smith JS, Green J, Berrington DG, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: A systematic review. Lancet 2003;361:1159-67.
47. Brinton LA, Tashima KT, Lehman HF, Levine RS, Mallin K, Savitz DA, et al. Epidemiology of cervical cancer by cell type. Cancer Res 1987;47: 1706-11.
48. Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk factors for cervical cancer by histology. Gynecol Oncol 1993;51: 301-6.
49. Parazzini F, La Vecchia C, Negri E, Fasoli M, Cecchetti G. Risk factors for adenocarcinoma of the cervix: A case-control study. Br J Cancer 1988;57:201-4.
50. Thomas DB, Ray RM. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1996;144:281-9.
51. Ursin G, Pike MC, Preston-Martin S, d'Ablaing G III, Peters RK. Sexual, reproductive, and other risk factors for adenocarcinoma of the cervix: results from a population-based case-control study (California, United States). Cancer Causes Control 1996;7:391-401.
52. Guleria K, Agarwal N, Mishra K, Gulati R, Mehendiratta A. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer? J Obstet Gynaecol Res 2004;30:181-7.
53. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002;105:166-9.
54. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: A systematic review. Obstet Gynecol Surv 2002;57:120-8.
55. Hill DA, Weiss NS, Voigt LF, Beresford SA. Endometrial cancer in relation to intra-uterine device use. Int J Cancer 1997;70:278-81.
56. Sturgeon SR, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al. Intrauterine device use and endometrial cancer risk. Int J Epidemiol 1997;26:496-500.
57. Rosenblatt KA, Thomas DB. Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1996;54:329-32.
58. Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. Br J Cancer 1994;70:672-3.
59. Castellsague X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer 1993;54:911-6.
60. Li HQ, Thomas DB, Jin SK, Wu F. Tubal sterilization and use of an IUD and risk of cervical cancer. J Womens Health Gend Based Med 2000;9:303-10.
61. Kohler U, Wuttke P. [Results of a case-control study of the current effect of various factors of cervical cancer risk. 2. Contraceptive behavior and the smoking factor]. Zentralbl Gynakol 1994;116:405-9.
62. Lassise DL, Savitz DA, Hamman RF, Baron AE, Brinton LA, Levines RS. Invasive cervical cancer and intrauterine device use. Int J Epidemiol 1991; 20:865-70.
63. Batar I. [The Szontagh IUD and cervix carcinoma (results of a 10-year follow up study)]. Orv Hetil 1990;131:1871-4.
64. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Effi cacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004;364:1757-65.
65. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.